Data unveils new insights into treatment for type 2 diabetes, obesity, cardiovascular, kidney and liver diseases Cardiometabolic diseases, including cardiovascular disease, obesity, type 2 diabetes, and MASH, are increasing in prevalence in the U.S. and are associated with high disease...
Novo Nordisk to present new cardiometabolic and renal data, including with semaglutide, at Kidney Week 2024, ObesityWeek®, The Liver Meeting®, and AHA Scientific Sessions 2024
Seaking AlphaSeeking Alpha / Seaking Alpha 3 hours ago 1 Views
Comments